Literature DB >> 11226084

Predicting the risk of death from heart failure after coronary artery bypass graft surgery.

S D Surgenor1, G T O'Connor, S J Lahey, R Quinn, D C Charlesworth, L J Dacey, R A Clough, B J Leavitt, G R Defoe, M Fillinger, W C Nugent.   

Abstract

UNLABELLED: Heart failure is the most common cause of death among coronary artery bypass graft (CABG) patients. In addition, most variation in observed mortality rates for CABG surgery is explained by fatal heart failure. The purpose of this study was to develop a clinical risk assessment tool so that clinicians can rapidly and easily assess the risk of fatal heart failure while caring for individual patients. Using prospective data for 8,641 CABG patients, we used logistic regression analysis to predict the risk of fatal heart failure. In multivariate analysis, female sex, prior CABG surgery, ejection fraction <40%, urgent or emergency surgery, advanced age (70-79 yr and >80 yr), peripheral vascular disease, diabetes, dialysis-dependent renal failure and three-vessel coronary disease were significant predictors of fatal postoperative heart failure. A clinical risk assessment tool was developed from this logistic regression model, which had good discriminating characteristics (receiver operating characteristic clinical source = 0.75, 95% confidence interval: 0.71, 0.78). IMPLICATIONS: In contrast to previous cardiac surgical scoring systems that predicted total mortality, we developed a clinical risk assessment tool that evaluates risk of fatal heart failure. This distinction is relevant for quality improvement initiatives, because most of the variation in CABG mortality rates is explained by postoperative heart failure.

Entities:  

Mesh:

Year:  2001        PMID: 11226084     DOI: 10.1097/00000539-200103000-00008

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

1.  Using biomarkers to improve the preoperative prediction of death in coronary artery bypass graft patients.

Authors:  Jeremiah R Brown; Todd A MacKenzie; Lawrence J Dacey; Bruce J Leavitt; John H Braxton; Benjamin M Westbrook; Robert E Helm; John D Klemperer; Carmine Frumiento; Gerald L Sardella; Cathy S Ross; Gerald T O'Connor
Journal:  J Extra Corpor Technol       Date:  2010-12

2.  Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin-3, and NT-ProBNP Before Cardiac Surgery.

Authors:  Sai Polineni; Devin M Parker; Shama S Alam; Heather Thiessen-Philbrook; Eric McArthur; Anthony W DiScipio; David J Malenka; Chirag R Parikh; Amit X Garg; Jeremiah R Brown
Journal:  J Am Heart Assoc       Date:  2018-07-07       Impact factor: 5.501

3.  Effect of glutamate infusion on NT-proBNP after coronary artery bypass grafting in high-risk patients (GLUTAMICS II): A randomized controlled trial.

Authors:  Jonas Holm; Gabriele Ferrari; Anders Holmgren; Farkas Vanky; Örjan Friberg; Mårten Vidlund; Rolf Svedjeholm
Journal:  PLoS Med       Date:  2022-05-09       Impact factor: 11.613

4.  Utility of NT-proBNP as an objective marker of postoperative heart failure after coronary artery bypass surgery: a prospective observational study.

Authors:  Huiqi Jiang; Jonas Holm; Örjan Friberg; Farkas Vanky; Mårten Vidlund; Bashir Tajik; Yanqi Yang; Rolf Svedjeholm
Journal:  Perioper Med (Lond)       Date:  2021-07-13

5.  Incidence, Determinants and Mortality of Heart Failure Associated With Medical-Surgical Procedures in Patients ≥ 65 Years of Age (from the Cardiovascular Health Study).

Authors:  Monali Shah; Carlos J Rodriguez; Traci M Bartz; Mary F Lyles; Jorge R Kizer; Gerard P Aurigemma; Julius M Gardin; John S Gottdiener
Journal:  Am J Cardiol       Date:  2021-06-24       Impact factor: 3.133

6.  The impact of glutamate infusion on postoperative NT-proBNP in patients undergoing coronary artery bypass surgery: a randomized study.

Authors:  Huiqi Jiang; Jonas Holm; Mårten Vidlund; Farkas Vanky; Örjan Friberg; Yanqi Yang; Rolf Svedjeholm
Journal:  J Transl Med       Date:  2020-05-11       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.